8-K/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K/A

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):  May 2, 2017

CTS CORPORATION

(Exact Name of Registrant as Specified in its Charter)

Indiana	1-4639	35-0225010
(State or other jurisdiction of incorporation)	(Commission File Number)	(1.R.S. Employer Identification No)

2375 Cabot Drive
Lisle, Illinois	60532
(Address of principal executive offices)	(Zip Code)

Registrant's Telephone Number, Including Area Code: (630) 577-8800

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K/A filing is intended to simultaneouslysatisfy the filing obligation

of the registrant under any of the following provisions (see General Instruction A.2.):

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a12)

☐Pre-commencement communications pursuant to Rule 14d 2(b) under the Exchange Act ( 17 CFR 240. l 4d2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4( c))

Explanatory Note

This Current Report on Form 8-K/A amends the Current Report on Form 8-K dated April 27, 2017 filed by CTS Corporation with the U.S. Securities and Exchange Commission. This amendment corrects data contained within certain charts on the investor presentation in Exhibit 99.1.

Item 7.01 Regulation FD Disclosure.

The investor presentation included as Exhibit 99.1 to this report may be presented at meetings with investors, analysts, and others, in whole or in part and possibly with modifications, during the fiscal year ending December 31, 2017.

The investor presentation includes financial information not prepared in accordance with generally accepted accounting principles (“GAAP”). A reconciliation of the non-GAAP financial measures to the most directly comparable financial measures prepared in accordance with generally accepted accounting principles, as required by Regulation G, is available within Exhibit 99.1 and on our website at www.ctscorp.com. The Company believes that the non-GAAP financial measures provide investors additional ways to view our operations which we believe provide a more complete understanding of our business than could be obtained absent these disclosures. We believe the non-GAAP financial measures also provide investors a useful tool to assess shareholder value.

By filing this Current Report on Form 8-K/A and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD.

The information contained in the investor presentation is summary information that is intended to be considered in the context of the Company's Securities and Exchange Commission (“SEC”) filings and other public announcements that the Company may make, by press release or otherwise, from time to time.  The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is warranted.  Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

The information presented in Item 7.01 of this Current Report on Form 8-K/A and Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits.

ExhibitDescription                            

99.1    April 2017 Investor Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 2, 2017	CTS CORPORATION
	By:	/s/ Ashish Agrawal
		Ashish Agrawal
		Vice President, Chief Financial Officer

EX-99.1

April 2017

Safe Harbor Statement This presentation contains statements that are, or may be deemed to be, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, any financial or other guidance, statements that reflect our current expectations concerning future results and events, and any other statements that are not based solely on historical fact. Forward-looking statements are based on management's expectations, certain assumptions and currently available information. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof and are based on various assumptions as to future events, the occurrence of which necessarily are subject to uncertainties. These forward-looking statements are made subject to certain risks, uncertainties and other factors, which could cause our actual results, performance or achievements to differ materially from those presented in the forward-looking statements. Examples of factors that may affect future operating results and financial condition include, but are not limited to: changes in the economy generally and in respect to the businesses in which CTS operates; unanticipated issues in integrating acquisitions; the results of actions to reposition our businesses; rapid technological change; general market conditions in the automotive, communications, and computer industries, as well as conditions in the industrial, defense and aerospace, and medical markets; reliance on key customers; unanticipated natural disasters or other events; the ability to protect our intellectual property; pricing pressures and demand for our products; unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters as well as any product liability claims; and risks associated with our international operations, including trade and tariff barriers, exchange rates and political and geopolitical risks. Many of these, and other, risks and uncertainties are discussed in further detail in Item 1A. of CTS’ Annual Report on Form 10-K. We undertake no obligation to publicly update our forward- looking statements to reflect new information or events or circumstances that arise after the date hereof, including market or industry changes. 2

2016 Sales: $397 Million Sales by Market:  Transportation – 66%  Industrial – 17%  Medical – 7%  Defense / Aerospace – 4%  Information Technology – 3%  Communications – 3% Sales by Region:  Americas – 58%  Asia – 30%  Europe – 12% Our Company Ticker: CTS (NYSE) Founded: 1896 Business: CTS is a leading designer and manufacturer of sensors, actuators and electronic components. Locations: 12 manufacturing locations throughout North America, Asia and Europe. Number of Employees: ~3,000 Globally Note: Sales by market and region based on trailing twelve months sales as of March 31, 2017 3

Our History - 120 Years of Innovation 4

Our Vision and Value Proposition We aim to be a leading provider of sensing and motion devices as well as connectivity components, enabling an intelligent and seamless world. 5

CTS Addressable Markets Growing to $6B by 2020 with Mid- Single Digit Growth Rates 6  Hydrophones for sonar applications  Military communication Organic Growth Drivers  100GB & 400GB Wireline Networks  Small Cell Deployment  3D and textile printing  New products for industrial controls  Actuators for harsh environments  RF Sensing for particulate filters  Medical 3D/4D ultrasound  HMI Control for medical devices Def/Aero Communications Industrial / IT Transportation Market Medical Product Categories

Product Applications in Passenger and Commercial Vehicles Engine Efficiency  Accelerator Pedal Module  Current Sensor  Gear Position Sensor  Throttle Position Sensor  Turbo Actuator  Turbo Position Sensor  Variable Valve Lift Sensor Key Customers New European Customer #1 New European Customer #2 7 Fuel Handling  Contacting Fuel Level Card Chassis / Driveline  Air Grill Shutter Actuator  Brake Pedal Sensor  Chassis Height Sensor  Transmission Speed Sensor  Transmission Range Sensor  Wheel Speed Sensor Occupant Safety  Seat Belt Buckle Switch  Seat Belt Tension Sensor  Seat Track Position Sensor Exhaust Management / Aftertreatment  EGR Position Sensor  DPF RF Sensor

Key Customers Industrial Printers, HVAC, Automation and Safety Products  Piezo micro-actuators  Switches  Encoders  Frequency Control  EMI Filters Product Applications in Industrial 8 Industrial Inkjet Printers Industrial HVAC

Key Customers Military Sonar and Communication Products  Piezo hydrophones  Piezo sonar arrays  Frequency Control  EMI Filters Product Applications in Defense / Aerospace 9 Unmanned Aerial Vehicles (UAV) Maritime Applications

Product Applications in Medical Key Customers Ultrasound / IVUS, Infusion Pumps, CPAPs and other medical devices  Single Crystal Piezo  Bulk Piezo  Encoders  Frequency Control  Piezo micro-valves  Switches  Joysticks 10 Ultrasound Equipment Infusion Pumps CPAP Machines

Positioning for Growth with Fundamental Market Trends 11 Autonomous Vehicle SMART Smart Home/ Building Unmanned Aerial Vehicles (Drones) Improved Medical Diagnosis Fuel Efficiency/ Vehicle Electrification Miniaturization Energy Harvesting EFFICIENT Green Buildings Remote Monitoring Industry 4.0 Internet of Things 5G & Small Cells CONNECTED Communications Information Technology Transportation IndustrialMedical Defense & Aerospace

Organic Growth 12 $299 $484 $560 $488 2013 2014 2015 2016 New Business Awards Organic Growth around Sense, Connect and Move 1Q Not Reported Total Booked Business Note: Total Booked Business represents open purchase orders, contractual commitments, and the total expected lifetime revenue from business awarded to CTS in multi-year platform awards. ($ Millions) Dec 2016 Mar 2017 $319 $263 $1,518 $1,538 Expected to ship in 2017

Targeted Acquisitions 13 Disciplined approach to acquisitions:  Returns in excess of cost of capital  Accretive to earnings  Maintain balance sheet strength  Synergy opportunities  Targeting 10% growth (both inorganic and organic) Expand Product Range Broaden Geographic Reach Enhance Technology Portfolio Strengthen Customer Relationships

The Road Ahead of Us LV I M CV C/IT AD LV/CV I C AD M IT/O LV I M CV C/IT AD 30-50% 20-30% 10-20% 10-20% 10-20% 5-15% Targeted End Markets Light Vehicles Industrial Medical Comm. / IT Commercial Vehicles Aviation/Defense EMS Divestiture Front End Refocus New Customers Regional Expansion Organic Projects M&A Legend: AD: Aviation/Defense C: Communications CV: Commercial Vehicles I: Industrial IT: Information Technology LV: Light Vehicles M: Medical O: Others Organic Growth Innovation M&A LV/CV I C DA M O 14

Single Crystal Technology Acquisition Current Applications – 3D & 4D Ultrasound, IVUS Future Applications – Hearing Aid, Pacemaker  Founded in 1997, located in Bolingbrook, IL  The industry leader for the design and manufacture of piezoelectric single crystals for use in the medical and defense industries; existing long-term relationships with blue chip OEM customers  The leading large scale, vertically integrated manufacturer of single crystals, having invested heavily in proprietary production processes and equipment  High definition medical ultrasound market expected to grow at >10% Wireless powering of pacemakers Implantable hearing aids to replace cochlear implants Intravascular Ultrasound (IVUS) detects plaque that causes heart disease Single crystal technology creates high definition imaging 15 Premium ultrasound machines utilize the technology for real- time 3D & 4D imaging of a fetus

$409 $404 $382 $397 2013 2014 2015 2016 2017E Sales $0.82 $0.97 $0.93 $1.08 2013 2014 2015 2016 2017E Adjusted Earnings Per Share $420 Note 1: Sales are from continuing operations. Adjusted EPS is as reported. Note 2: 2017E represents guidance provided on April 27, 2017. Annual Financial Performance Trend 16 $405 $1.22 $1.12 ($ Millions except Adjusted Earnings Per Share) Booked Business $263 Q1 Actual $100

Equity 77% Bank Debt 23% $135 $157 $114 $122 $75 $91 $90 $95 2014 2015 2016 Q1 2017 Note 1: Change in Cash/Debt in 2016 due to Single Crystal Acquisition Note 2: Total available credit increased from $200M to $300M in 2Q 2016 Capital Structure Cash and Debt Net Debt $(60) $(66) Current Capital Structure DebtCash $(24) $(27) 17 ($ Millions except percentages)

Capital Structure Leverage = 1.0x - 2.5x EBITDA Operating Cash Flow Return Capital to Shareholders ~4% of Sales 20-40% of Free Cash Flow 12-14% of Sales 60-80% of Free Cash Flow Target Capital Deployment – Disciplined Approach Growth AcquisitionsInvestment Dividends & Buybacks 18

Financial Framework 19 2012 2016 Long-Term Target Range Gross Margin 30.0% 35.4% 34-37% SG&A Expense 20.7% 15.5% 13-15% R&D Expense 6.9% 6.1% 5-7% CapEx 2.6% 5.2% ~4% Targeting 10% Annual Growth (Organic + Inorganic)

Appendix 20

CTS Core Values 21

Financial Summary Note 1: See Regulation G reconciliations from GAAP to Non-GAAP measures and adjustments. Note 2: All figures are from continuing operations except for Adjusted Diluted EPS (As Reported), Operating Cash Flow and Total Debt / Capitalization ($ Millions, except percentages and Adjusted Diluted EPS) Net Sales Adjusted Diluted EPS (As Reported) Operating Cash Flow Total Debt / Capitalization Depreciation and Amortization 2015 $382.3 $0.93 $39.1 24.4% $16.3 2014 $404.0 $0.97 $33.3 20.6% $17.0 2013 $409.5 $0.82 $37.6 20.2% $17.3 2012 $304.5 $0.64 $41.7 36.4% $13.5 Adjusted EBITDA Adjusted EBITDA % of Sales $60.9 15.9% $66.5 16.5% $54.5 13.3% $28.6 9.4% 2016 $396.7 $1.08 $47.2 22.1% $19.0 $77.4 19.5% 22 Gross Margin Gross Margin % of Sales $127.1 33.2% $130.0 32.2% $121.4 29.6% $91.5 30.0% $140.4 35.4% Q1 2017 $100.2 $0.26 $9.8 22.6% $4.7 $18.0 18.0% $34.2 34.2%

Regulation G Schedules ($ Millions, except percentages) Adjusted EBITDA 23 2017 2016 2016 2015 2014 2013 2012 Net earnings from continuing operations 8.5$ 7.9$ 34.4$ 7.0$ 26.5$ 2.0$ 13.5$ Depreciation and amortization expense 4.7$ 4.0$ 19.0$ 16.3$ 17.0$ 17.3$ 13.5$ Interest expense 0.7$ 0.8$ 3.7$ 2.6$ 2.3$ 3.3$ 2.6$ Tax expense 3.7$ 4.1$ 22.9$ 5.3$ 12.8$ 16.1$ 1.0$ EBITDA from continuing operations 17.6$ 16.8$ 80.0$ 31.2$ 58.6$ 38.6$ 30.5$ Charges (credits) to EBITDA from continuing operations: Restructuring and asset impairment charges 0.8$ -$ 3.0$ 15.2$ 7.9$ 11.8$ 4.5$ Loss (gain) on sale-leaseback -$ -$ 0.1$ -$ -$ -$ (10.3)$ Gain on sale of facilities, net of expenses -$ -$ (11.1)$ -$ -$ -$ -$ Non-recurring environmental charge -$ -$ -$ 14.5$ -$ -$ -$ Foreign currency (gain) loss (0.4)$ 0.2$ 3.8$ -$ -$ -$ -$ Legal costs, acquisition-related costs, and CEO search costs -$ 0.8$ 0.8$ -$ -$ 4.1$ 3.9$ Lease termination charge -$ -$ 0.8$ -$ -$ -$ -$ Total adjustments to reported operating earnings from continuing operations 0.4$ 1.0$ (2.6)$ 29.7$ 7.9$ 15.9$ (1.9)$ Adjusted EBITDA from continuing operations 18.0$ 17.8$ 77.4$ 60.9$ 66.5$ 54.5$ 28.6$ Sales from continuing operations 100.2$ 96.7$ 396.7$ 382.3$ 404.0$ 409.5$ 304.5$ Adjusted EBITDA as a % of sales from continuing operations 18.0% 18.4% 19.5% 15.9% 16.5% 13.3% 9.4% Full YearQ1

Regulation G Schedules Adjusted Diluted EPS ($ Millions, except percentages) Total Debt to Capitalization 24 2017 2016 2016 2015 2014 2013 2012 Total debt (A) 95.0$ 141.3$ 90.1$ 90.7$ 75.0$ 75.0$ 153.5$ Total shareholders' equity (B) 326.1$ 288.2$ 317.9$ 281.7$ 289.8$ 296.9$ 267.8$ Total capitalization (A+B) 421.1$ 429.5$ 408.0$ 372.4$ 364.8$ 371.9$ 421.3$ Total debt to capitalization 22.6% 32.9% 22.1% 24.4% 20.6% 20.2% 36.4% As of December 31Q1 2017 2016 2016 2015 2014 2013 2012 2013 2012 Diluted earnings (loss) per share 0.25$ 0.24$ 1.03$ 0.21$ 0.78$ 0.06$ 0.39$ (0.12)$ 0.59$ Tax affected charges (credits) to reported diluted earnings per share: Restructuring and asset impairment charges 0.02$ -$ 0.06$ 0.40$ 0.18$ 0.28$ 0.10$ 0.28$ 0.19$ Increase in valuation allowance and revaluation of deferred taxes as a result of restructuring activities -$ -$ 0.07$ -$ 0.01$ -$ -$ -$ -$ (Gain) loss on sale-leaseback -$ -$ -$ -$ -$ -$ (0.23)$ -$ (0.23)$ Gain on sale of facilities, net of expenses -$ -$ (0.22)$ -$ -$ -$ -$ -$ -$ Legal costs, acquisition-related costs, and CEO search costs -$ 0.01$ 0.02$ -$ -$ 0.07$ 0.09$ 0.07$ 0.09$ Lease termination charge -$ -$ 0.02$ -$ -$ -$ -$ -$ -$ EMS divestiture -$ -$ -$ -$ -$ -$ -$ 0.25$ -$ Non-recurring environmental charge -$ -$ -$ 0.27$ -$ -$ -$ -$ -$ Foreign currency (gain) loss (0.01)$ 0.01$ 0.09$ -$ -$ -$ -$ -$ -$ Tax impact of cash repatriation -$ -$ -$ 0.26$ -$ 0.31$ -$ 0.31$ -$ Tax impact of U.K. deferred tax asset write-off -$ -$ -$ -$ -$ 0.03$ -$ 0.03$ -$ Increase in recognition of foreign valuation allowance -$ -$ 0.03$ 0.10$ -$ -$ -$ -$ -$ Increase in reserve on uncertain tax benefits -$ -$ -$ 0.17$ -$ -$ -$ -$ -$ Tax impact of non-recurring stock compensation charge -$ -$ (0.02)$ -$ -$ -$ -$ -$ -$ Change in treatment of certain foreign taxes -$ -$ -$ (0.48)$ -$ -$ -$ -$ -$ Adjusted diluted earnings per share 0.26$ 0.26$ 1.08$ 0.93$ 0.97$ 0.75$ 0.35$ 0.82$ 0.64$ * Includes discontinued operations Full Year - From Continuing Operations Full Year - As Reported *Q1